[1] 胡志成, 蒋超, 郑黎晖, 等. 2019年中国心房颤动医疗质量控制报告[J]. 中国循环杂志, 2020,35(5): 427-437.[2] JOGLAR J A, CHUNG M K, ARMBRUSTER A L, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines[J]. Circulation, 2024, 149(1): e1-e156. [3] 中华医学会心血管病学分会, 中国生物医学工程学会心律分会. 心房颤动诊断和治疗中国指南[J]. 中华心血管病杂志, 2023, 51(6): 572-618. [4] LEE M Y, HAN S, BANG O Y, et al. Drug utilization pattern of oral anticoagulants in patients with atrial fibrillation: a nationwide population-based study in Korea[J]. Adv Ther, 2022, 39(7): 3112-3130. [5] ZIELINSKI G D,VAN REIN N, TEICHERT M, et al. Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: a surveillance study[J]. Res Pract Thromb Haemost, 2019, 4(1): 141-153. [6] GUO Y, WANG H, KOTALCZYK A, et al. One-year follow-up results of the optimal thromboprophylaxis in elderly Chinese patients with atrial fibrillation(ChiOTEAF) registry[J]. J Arrhythm, 2021, 37(5): 1227-1239. [7] JACKEVICIUS C A, TSADOK M A, ESSEBAG V, et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation[J]. Heart, 2017, 103(17): 1331-1338. [8] GARCÍA RODRÍGUEZ L A, CEA SORIANO L, MUNK HALD S, et al. Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke[J]. Heart,2020, 107(7): 542-548. [9] TSAO C W, ADAY A W, ALMARZOOQ Z I, et al. Heartdisease and stroke statistics-2023 update: a report from the American heart association[J]. Circulation, 2023, 147(8): e93-e621. [10] COOLS F, JOHNSON D, CAMM A J, et al. Risks associated with discontinuation of oral anticoagulation in newly diagnosed patients with atrial fibrillation: results from the GARFIELD-AF Registry[J]. J Thromb Haemost, 2021, 19(9): 2322-2334. [11] BRÍZIDO C, FERREIRA A M, LOPES P, et al. Medication adherence to direct anticoagulants in patients with non-valvular atrial fibrillation - a real world analysis[J]. Rev Port Cardiol, 2021, 40(9): 669-675. [12] PAQUETTE M, RIOU FRANÇA L, TEUTSCH C, et al. Persistence with dabigatran therapy at 2 years in patients with atrial fibrillation[J]. J Am Coll Cardiol, 2017, 70(13): 1573-1583. [13] RAPARELLI V, PROIETTI M, CANGEMI R, et al. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants[J]. Thromb Haemost, 2017, 117(2): 209-218. [14] HERNANDEZ I, HE M, CHEN N, et al. Trajectories of oral anticoagulation adherence among medicare beneficiaries newly diagnosed with atrial fibrillation[J]. J Am Heart Assoc, 2019, 8(12): e011427. [15] ZHU L, ZHANG X, YANG J. Analysis of influencing factors of compliance with non-vitamin K antagonist oral anticoagulant in patients with nonvalvular atrial fibrillation and correlation with the severity of ischemic stroke[J]. Evid Based Complement Alternat Med, 2021, 2021: 1021127. [16] CHAO T F, LIU C J, LIN Y J, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study[J]. Circulation, 2018, 138(1): 37-47. |